Cyxone appoints Carl-Magnus Högerkorp as COO strengthening immunology core competencies
Cyxone today announces that Carl-Magnus Högerkorp is appointed new COO in the company from May 20th, 2021. With broad experience from work within the field of immunology and autoimmune diseases, as well as extensive international experience and previous management roles in the biotech sector, Carl-Magnus is an important part of Cyxone’s continued ambition to strengthen and develop the company.
Carl-Magnus holds a PhD in immunology from Lund University, as well as an MBA from Lund University School of Economics and Management. He started his career with a postdoc position at the Vaccine Research Center, National Institutes of Health in Maryland, USA, where he worked with HIV and the development of HIV vaccines. Thereafter, Carl-Magnus started working for Novo Nordisk and their initiatives within inflammation and autoimmune diseases, where he among other things led a discovery project and held various research roles within molecular genetics, translational immunology and cellular pharmacology. Carl-Magnus has thereafter held leading positions in a number of different biotech companies in Lund, Sweden. As Chief Scientific Officer at Xintela, he worked with regenerative medicine and oncology, and was part of the introduction of the company on Nasdaq First North. Carl-Magus was subsequently appointed CEO at start-up Edvince AB and their stroke treatment in clinical phase. Most recently, he has held the position as CEO at Canimguide Therapeutics, developing a concept within immuno-oncology in clinical phase. Carl-Magnus has also been part of starting up ImModulate Pharma AB, where he has had the position as CEO during 2021.
“Cyxone has a portfolio of very interesting molecules with prerequisites for many therapeutic areas, as they regulate central immunomodulatory mechanisms. We’ve now initiated the study with Rabeximod for Covid-19 which will be exciting to continue working on, and I see possibilities to also look at other autoimmune and inflammatory conditions for the molecule. I also find the peptide T20K very interesting - especially as MS is a serious disease with large medical needs. There are also other aspects of the company that are very interesting, with a real understanding of the market demands and good and transparent communications, which are important cornerstones and a foundation in developing the company further. Cyxone is working with large therapeutic areas and that’s bold, and has drug candidates with the potential to make a difference. This is an exciting opportunity.” says Carl-Magnus Högerkorp.
Carl-Magnus takes over the role as COO from Malin Berthold, who is leaving the company.
“Malin has generated value during her tenure as COO at Cyxone with the initiation of Phase 2 trials for Rabeximod in patients with Covid-19, and with her capabilities in drug development supported the progress in all of Cyxone’s programs. Her contributions have been much appreciated and we wish her the best of luck in her future endeavours”, says Tara Heitner, CEO and continues: “I am pleased to welcome Carl-Magnus to the Cyxone team and look forward to working closely with him on our current programs. As we grow and expand our pipeline his experience in leadership, immunology and autoimmune disease as well as his understanding and enthusiasm for the potential of our assets brings additional innovation and excitement for collaboration to the team.”
Contact
Tara Heitner, CEO
Tel: +46 70 781 88 08
Email: tara.heitner@cyxone.com
Adelgatan 21
211 22 Malmö, Sweden
About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, ca@mangold.se. For more information, please visit www.cyxone.com.
Tags: